Printer Friendly

ICOS ANNOUNCES RESEARCH AGREEMENT WITH OREGON HEALTH SCIENCES UNIVERSITY

 SEATTLE, Feb. 25 /PRNewswire/ -- ICOS Corp. (NASDAQ: ICOS) announced today a research collaboration with Oregon Health Sciences University (OHSU). The new agreement covers novel localization proteins for certain enzymes believed responsible for triggering disease. Under the terms of the collaborative agreement, ICOS will have exclusive rights to the technology. In return, OHSU may receive future royalties on certain products and the principle investigators will receive laboratory support.
 "The agreement allows ICOS to extend its efforts in the areas of selective enzyme modulation," said Dr. Christopher S. Henney, ICOS' executive vice president and scientific director. "The agreement allows collaboration between our scientists and Dr. John Scott of OHSU whose work builds on the discoveries of the recent Nobel winner, Edwin Krebs."
 ICOS Corp. is a Seattle-based biopharmaceutical company founded to develop medications for the treatment of chronic inflammatory diseases. Primary targets of the company's drug and research development program include asthma, multiple sclerosis and rheumatoid arthritis.
 -0- 2/25/93
 /CONTACT: Janice M. LeCocq of ICOS, 206-485-1900/
 (ICOS)


CO: ICOS Corp.; Oregon Health Sciences University ST: Washington IN: MTC SU:

SW-LM -- SE002 -- 0234 02/25/93 08:32 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 1993
Words:188
Previous Article:AGOURON CEO ISSUES STATEMENT CONCERNING RECENT STOCK PRICE DECLINE
Next Article:SUMMIT HEALTH TO ACQUIRE SIX SURGERY SUITES AND TWO URGENT CARE CENTERS
Topics:


Related Articles
ICOS ANNOUNCES RESEARCH AGREEMENT WITH UNIVERSITY OF UTAH
ICOS ANNOUNCES RESEARCH AGREEMENT WITH DOHENY EYE INSTITUTE
CAREMARK SELECTED TO PROVIDE HOME CARE SERVICES UNDER NEW OREGON MANAGED CARE PROGRAM
ICOS AND ABBOTT ESTABLISH COLLABORATION
ICOS AND THE UNIVERSITY OF UTAH ANNOUNCE PUBLICATION IN NATURE ON PAF-AH
Lilly and ICOS Establish a Joint Venture to Develop and Market PDE5 Compounds to Treat Sexual Dysfunction.
Atherogenics Appoints Don Kirksey, Ph.D., as VP Business and Corporate Development.
Leaders Gather at Phosphodiesterases in Disease.
The ICOS Directorship.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters